- Home
- LEO vs GKOS Comparison
LEO vs GKOS Comparison
Compare LEO & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEO
- GKOS
- Stock Information
- Founded
- LEO 1987
- GKOS 1998
- Country
- LEO United States
- GKOS United States
- Employees
- LEO N/A
- GKOS N/A
- Industry
- LEO Trusts Except Educational Religious and Charitable
- GKOS Medical/Dental Instruments
- Sector
- LEO Finance
- GKOS Health Care
- Exchange
- LEO Nasdaq
- GKOS Nasdaq
- Market Cap
- LEO N/A
- GKOS 5.1B
- IPO Year
- LEO N/A
- GKOS 2015
- Fundamental
- Price
- LEO $5.83
- GKOS $96.63
- Analyst Decision
- LEO
- GKOS Strong Buy
- Analyst Count
- LEO 0
- GKOS 13
- Target Price
- LEO N/A
- GKOS $155.00
- AVG Volume (30 Days)
- LEO 200.2K
- GKOS 1.0M
- Earning Date
- LEO 01-01-0001
- GKOS 04-30-2025
- Dividend Yield
- LEO 4.01%
- GKOS N/A
- EPS Growth
- LEO N/A
- GKOS N/A
- EPS
- LEO 0.04
- GKOS N/A
- Revenue
- LEO N/A
- GKOS $383,481,000.00
- Revenue This Year
- LEO N/A
- GKOS $27.84
- Revenue Next Year
- LEO N/A
- GKOS $27.99
- P/E Ratio
- LEO $152.00
- GKOS N/A
- Revenue Growth
- LEO N/A
- GKOS 21.85
- 52 Week Low
- LEO $4.98
- GKOS $77.91
- 52 Week High
- LEO $6.50
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- LEO 43.70
- GKOS 50.06
- Support Level
- LEO $5.67
- GKOS $87.17
- Resistance Level
- LEO $5.88
- GKOS $98.86
- Average True Range (ATR)
- LEO 0.12
- GKOS 5.59
- MACD
- LEO 0.01
- GKOS 1.78
- Stochastic Oscillator
- LEO 50.00
- GKOS 88.89
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.